29.39
0.72 (2.51%)
| 前收盘价格 | 28.67 |
| 收盘价格 | 29.33 |
| 成交量 | 416,692 |
| 平均成交量 (3个月) | 1,445,119 |
| 市值 | 1,319,678,720 |
| 市盈率 (P/E TTM) | 3.83 |
| 股市价格/股市净资产 (P/B) | 3.29 |
| 52周波幅 | |
| 利润日期 | 6 Nov 2025 |
| 稀释每股收益 (EPS TTM) | -2.20 |
| 总债务/股东权益 (D/E MRQ) | 0.05% |
| 流动比率 (MRQ) | 23.31 |
| 营业现金流 (OCF TTM) | -66.65 M |
| 杠杆自由现金流 (LFCF TTM) | -42.10 M |
| 资产报酬率 (ROA TTM) | -31.68% |
| 股东权益报酬率 (ROE TTM) | -48.22% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | MBX Biosciences, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
| 分析师共识 | -0.5 |
| 内部交易活动 | NA |
| 价格波动 | -4.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | 0.5 |
| 平均 | -0.38 |
|
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 3.12% |
| 机构持股比例 | 106.60% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Frazier Life Sciences Management, L.P. | 30 Sep 2025 | 6,652,013 |
| Orbimed Advisors Llc | 30 Sep 2025 | 4,002,887 |
| Nea Management Company, Llc | 30 Sep 2025 | 3,614,486 |
| Nvp Associates, Llc | 30 Sep 2025 | 2,136,335 |
| Ecor1 Capital, Llc | 30 Sep 2025 | 2,123,604 |
| Cormorant Asset Management, Lp | 30 Sep 2025 | 1,225,000 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 80.00 (Oppenheimer, 172.20%) | 购买 |
| 中 | 53.00 (80.33%) | |
| 低 | 18.00 (Goldman Sachs, -38.76%) | 卖出 |
| 平均值 | 55.17 (87.72%) | |
| 总计 | 5 购买, 1 卖出 | |
| 平均价格@调整类型 | 22.91 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Stifel | 19 Dec 2025 | 50.00 (70.13%) | 购买 | 29.39 |
| Goldman Sachs | 04 Dec 2025 | 18.00 (-38.75%) | 卖出 | 30.54 |
| Guggenheim | 10 Nov 2025 | 77.00 (161.99%) | 购买 | 24.49 |
| 23 Sep 2025 | 84.00 (185.81%) | 购买 | 18.96 | |
| Truist Securities | 15 Oct 2025 | 50.00 (70.13%) | 购买 | 13.95 |
| Mizuho | 24 Sep 2025 | 56.00 (90.54%) | 购买 | 20.10 |
| Oppenheimer | 23 Sep 2025 | 80.00 (172.20%) | 购买 | 18.96 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合